“`html
Safety and Efficacy of Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Treating Aging Frailty
Key Findings:
• Intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs) showed significant improvements in quality of life and physical performance in patients with aging frailty.
• The treatment also led to a reduction in chronic inflammation, indicating its potential as a promising therapeutic option for aging frailty.
Practical Solutions:
• AI-driven platform DocSym consolidates clinical protocols and research, making it easier for clinicians to access essential knowledge for safe and effective treatments.
• Mobile apps support scheduling, treatment monitoring, and telemedicine, contributing to streamlined operations and improved patient care in the healthcare environment.
Value:
• The study demonstrates the safety and effectiveness of HUC-MSC therapy in improving the quality of life and physical function of aging frailty patients, offering a potential treatment option for this condition.
• AI-driven solutions such as DocSym and mobile apps can enhance clinic workflows, improve patient outcomes, and expand digital services, ultimately benefiting both patients and healthcare providers.
“`
